We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.13B
AUM Growth
+$109M
Cap. Flow
-$57.7M
Cap. Flow %
-5.12%
Top 10 Hldgs %
41.36%
Holding
140
New
44
Increased
20
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$38.4M
2
LLY icon
Eli Lilly
LLY
+$37.9M
3
ONCR
Oncorus, Inc.
ONCR
+$20.9M
4
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
+$19.8M
5
CCCC icon
C4 Therapeutics
CCCC
+$12.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$56.2M
2
ABBV icon
AbbVie
ABBV
+$43.2M
3
AMGN icon
Amgen
AMGN
+$28M
4
FOLD
Amicus Therapeutics
FOLD
+$20M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 67.85%
2 Technology 8.78%
3 Industrials 3.15%
4 Consumer Discretionary 1.89%
5 Communication Services 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PASG icon
126
Passage Bio
PASG
$14.4M
– –
-13,302
Closed -$3.49M
PRGO icon
127
Perrigo
PRGO
$1.4B
– –
-71,559
Closed -$3.29M
QQQ icon
128
PUT
Invesco QQQ Trust
QQQ
$453B
– –
-210,000
Closed -$58.3M
SEDG icon
129
SolarEdge
SEDG
$2.51B
– –
-4,017
Closed -$957K
SNY icon
130
Sanofi
SNY
$103B
– –
-1,120,000
Closed -$56.2M
XCUR icon
131
Exicure
XCUR
$10.2M
– –
-4,917
Closed -$1.29M
NBSE
132
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-7,500
Closed -$1.14M
RETA
133
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-59,139
Closed -$5.76M
SIOX
134
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-1,152,998
Closed -$5.33M
ALBO
135
DELISTED
Albireo Pharma Inc
ALBO
– –
-173,600
Closed -$5.79M
ARNA
136
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-75,000
Closed -$5.61M
PAND
137
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
– –
-95,000
Closed -$1.09M
MYOK
138
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-81,000
Closed -$11M
ARYBU
139
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
– –
-499,000
Closed -$5.49M
2 3 4 5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sphera Funds Management held 140 positions worth $1.13B, up 11% from $1.02B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management withdrew a net $57.7M in Q4 2020, closing 30 positions and reducing 33 holdings. Its most notable exit was Sanofi, an estimated $56.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Bristol-Myers Squibb worth $38.8M.

  • Sphera Funds Management's largest Q4 2020 buy was Bristol-Myers Squibb: 625,000 shares worth $38.8M.
  • Sphera Funds Management added most to Eli Lilly in Q4 2020, an estimated $37.9M increase.
  • Sphera Funds Management's biggest Q4 2020 reduction was AbbVie, cutting an estimated $43.2M.
  • Sphera Funds Management fully exited Sanofi in Q4 2020, selling an estimated $56.2M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $1.13B portfolio in Q4 2020.
  • Sphera Funds Management opened 44 new positions and closed 30 in Q4 2020.
  • Sphera Funds Management's portfolio value rose 11% quarter-over-quarter to $1.13B.

Based on Sphera Funds Management's 13F filing for Q4 2020, filed 16 Feb 2021.